Graham Hetherington has a broad range of experience in senior financial roles having most recently held positions as the Chief Financial Officer of Bacardi (2007) and Allied Domecq PLC (1999-2005). In his role at Allied Domecq he was a key member of the team that transformed the performance, shape and reputation of Allied Domecq, doubling shareholder value and overseeing a period of consistent earnings per share growth.
A Fellow of the Chartered Institute of Management Accountants (FCMA), Graham has valuable experience of leading finance functions for consumer brand driven organisations within the food and drink industry.
As previously announced, on June 18th 2008 Shire's current Chief Financial Officer, Angus Russell becomes Chief Executive Officer; he will also be acting Chief Financial Officer until 1st July, when Graham Hetherington takes up the position. On June 18th, Shire's current Chief Executive Officer Matthew Emmens becomes Chairman and Non-Executive Director, and Shire's current Chairman, Dr James Cavanaugh retires from the Shire Board.
Angus Russell, Shire current Chief Financial Officer commented :
"Graham brings to Shire a track record of delivering good financial results combined with extensive strategy, M&A and corporate development expertise in the rapidly changing food and drink industry."
Matthew Emmens, Shire current Chief Executive Officer added :
"We welcome Graham to the Shire Board. In addition to his contributions as the Company's Chief Financial Officer, he brings a wealth of financial experience as well as a new perspective from another highly competitive industry."
Graham Hetherington added :
"Shire stands out as a leader in its field because it has a differentiated model, a clear strategy and it is prepared to take calculated risks in the interest of consistently delivering growth and shareholder value. I'm pleased to be joining a company with such a track record of innovation and I'm looking forward to bringing my experience of strong consumer driven industries to the Shire organisation."
SHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and
hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent
opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
www.shire.com
A Fellow of the Chartered Institute of Management Accountants (FCMA), Graham has valuable experience of leading finance functions for consumer brand driven organisations within the food and drink industry.
As previously announced, on June 18th 2008 Shire's current Chief Financial Officer, Angus Russell becomes Chief Executive Officer; he will also be acting Chief Financial Officer until 1st July, when Graham Hetherington takes up the position. On June 18th, Shire's current Chief Executive Officer Matthew Emmens becomes Chairman and Non-Executive Director, and Shire's current Chairman, Dr James Cavanaugh retires from the Shire Board.
Angus Russell, Shire current Chief Financial Officer commented :
"Graham brings to Shire a track record of delivering good financial results combined with extensive strategy, M&A and corporate development expertise in the rapidly changing food and drink industry."
Matthew Emmens, Shire current Chief Executive Officer added :
"We welcome Graham to the Shire Board. In addition to his contributions as the Company's Chief Financial Officer, he brings a wealth of financial experience as well as a new perspective from another highly competitive industry."
Graham Hetherington added :
"Shire stands out as a leader in its field because it has a differentiated model, a clear strategy and it is prepared to take calculated risks in the interest of consistently delivering growth and shareholder value. I'm pleased to be joining a company with such a track record of innovation and I'm looking forward to bringing my experience of strong consumer driven industries to the Shire organisation."
SHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and
hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent
opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
www.shire.com